Merck's Oral Cholesterol Drug Enlicitide Shows 64.6% LDL Reduction in Late-Stage Trial
核心洞察
Merck (搜索)'s oral non-statin drug enlicitide decanoate reduced bad cholesterol by up to 64.6% from baseline in an eight-week late-stage trial when added to background statin treatment.
The drug demonstrated superior efficacy compared to existing non-statin therapies, reducing LDL-C by 56.7% versus bempedoic acid and 36.0% versus ezetimibe in head-to-head comparisons.
Enlicitide works by blocking PCSK9 protein and could represent a significant pipeline asset for Merck (搜索) as it seeks new blockbuster candidates ahead of Keytruda's patent expiration.
Merck (搜索) announced positive results from a late-stage trial of its oral cholesterol-lowering drug enlicitide decanoate, which reduced bad cholesterol by up to 64.6% from baseline when added to background statin treatment. The eight-week head-to-head trial provides crucial data for the company as it seeks its next blockbuster candidate ahead of Keytruda's expected patent expiration by the end of the decade.
Trial Design and Patient Population
The study tested enlicitide decanoate in patients with hypercholesterolemia (搜索), a condition characterized by elevated levels of LDL (bad) cholesterol in the blood that often leads to plaque buildup in the arteries. According to government data, hypercholesterolemia affects approximately 73.5 million Americans and increases the risk of heart disease (搜索).
The eight-week trial directly compared enlicitide with existing oral non-statin therapies, including bempedoic acid and ezetimibe, in patients already receiving background statin treatment.
Efficacy Results
Enlicitide demonstrated superior efficacy across multiple comparisons in the head-to-head trial. The drug reduced LDL cholesterol by 56.7% compared with bempedoic acid, a non-statin oral cholesterol-lowering drug, and by 36.0% compared with ezetimibe, which works by blocking cholesterol absorption in the gut.
When compared to a combination therapy of both bempedoic acid and ezetimibe, enlicitide still showed meaningful benefit, reducing LDL-C by 28.1%.
Mechanism of Action and Development Timeline
Enlicitide works by blocking PCSK9, a protein that plays a crucial role in regulating cholesterol levels, while statins block an enzyme the liver uses to make cholesterol. This represents a different approach from existing therapies in the cholesterol management landscape.
The drug has received the U.S. Food and Drug Administration Commissioner's National Priority Voucher, which could accelerate the approval timeline. According to Scotiabank analyst Louise Chen, approval could come as early as 2026.
Previous Trial Data and Market Potential
In September, enlicitide showed meaningful reductions in LDL cholesterol compared with placebo during a 24-week trial, providing additional support for its efficacy profile.
Chen described the drug as potentially one of Merck (搜索)'s "most underappreciated pipeline assets with peak sales potential of tens of billions of dollars," highlighting the significant commercial opportunity in the cholesterol management market.
Competitive Landscape
Similar treatments currently in development include AstraZeneca's oral PCSK9 inhibitor AZD0780 and Verve Therapeutics' gene-editing therapy to lower cholesterol, indicating growing industry interest in novel approaches to cholesterol management beyond traditional statin therapy.